Department of Urology, Foch Hospital, 40 rue Worth, 92150, Suresnes, France.
University of Versailles-Saint-Quentin-en-Yvelines, Versailles, France.
BMC Cancer. 2021 Jan 14;21(1):61. doi: 10.1186/s12885-020-07780-7.
Prostate cancer among black men is known to have specific molecular characteristics, especially the androgen receptor or enzymes related to the androgen metabolism. These targets are keys to the action of new hormonal therapies. Nevertheless, literature has a lack of data regarding black men. We aimed to gather the available literature data on new hormonal therapies among black populations.
We conducted a literature review from the PubMed / MEDLINE database until October 2020. All clinical studies of new hormonal therapies and black populations, regardless of methodology, were included.
Four studies provided data on new hormonal therapies in black populations. Three studies reported a PSA decline in black patients treated with Abiraterone, higher in black men than in white men. Overall survival also appears to be higher in black patients treated with Abiraterone only or first.
Few articles have evaluated the effectiveness and safety of use of these treatments among black populations. The first results seem to show that Abiraterone can provide a benefit in overall survival in black populations. Prospective studies are needed to answer these questions in the future.
众所周知，黑人男性的前列腺癌具有特定的分子特征，尤其是雄激素受体或与雄激素代谢相关的酶。这些靶点是新型激素疗法作用的关键。然而，文献中缺乏关于黑人男性的数据。我们旨在收集有关黑人人群中新型激素疗法的现有文献数据。
我们对 PubMed/MEDLINE 数据库进行了文献回顾，截至 2020 年 10 月。纳入了所有关于新型激素疗法和黑人人群的临床研究，无论其方法如何。
四项研究提供了关于黑人人群中新型激素疗法的数据。三项研究报告了接受阿比特龙治疗的黑人患者 PSA 下降，黑人男性比白人男性更高。仅接受阿比特龙或一线治疗的黑人患者的总生存期似乎也更高。
很少有文章评估了这些治疗方法在黑人人群中的疗效和安全性。初步结果似乎表明，阿比特龙可以为黑人人群的总生存期带来获益。未来需要前瞻性研究来回答这些问题。
